A one-year prospective study of the safety, tolerability and pharmacokinetics of the highest available dose of paliperidone palmitate in patients with schizophrenia

BMC Psychiatry

Volumn 12, Issue , 2012, Pages

  Coppola, Danielle ^a   Liu, Yanning ^a   Gopal, Srihari ^a   Remmerie, Bart ^b   Samtani, Mahesh N ^a   Hough, David W ^a   Nuamah, Isaac ^a   Sulaiman, Ahmad ^c   Pandina, Gahan ^a  

^a JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^b JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^c UNIVERSITY OF MALAYA   (Malaysia)

Author keywords

Antipsychotics; Long term therapy; Paliperidone palmitate; Pharmacokinetics; Safety; Schizophrenia

Indexed keywords

CLONAZEPAM; DIAZEPAM; LORAZEPAM; PALIPERIDONE; ZOLPIDEM; ISOXAZOLE DERIVATIVE; NEUROLEPTIC AGENT; PALMITIC ACID DERIVATIVE;

ADULT; AGED; AKATHISIA; ARTICLE; ASTHENIA; BLOOD SAMPLING; BODY MASS; CONCENTRATION RESPONSE; DELTOID MUSCLE; DRUG BLOOD LEVEL; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSTONIA; FEMALE; GLUTEUS MAXIMUS MUSCLE; HUMAN; INJECTION SITE PAIN; INSOMNIA; LONG TERM CARE; MAINTENANCE DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MENTAL PATIENT; OPEN STUDY; ORTHOSTATIC HYPOTENSION; POSITIVE AND NEGATIVE SYNDROME SCALE; PROLACTIN BLOOD LEVEL; PROSPECTIVE STUDY; RECOMMENDED DRUG DOSE; RHINOPHARYNGITIS; SCHIZOPHRENIA; SIDE EFFECT; TACHYCARDIA; TREMOR; UPPER RESPIRATORY TRACT INFECTION; WEIGHT CHANGE; ADOLESCENT; BLOOD; CLINICAL TRIAL; DOSE RESPONSE; DRUG ADMINISTRATION; INTRAMUSCULAR DRUG ADMINISTRATION; MIDDLE AGED; MULTICENTER STUDY; PHASE 1 CLINICAL TRIAL; PSYCHOLOGICAL RATING SCALE; PSYCHOLOGY; STATISTICS; TREATMENT FAILURE; CONTROLLED STUDY; EXTRAPYRAMIDAL SYMPTOM; HEADACHE;

ADOLESCENT; ADULT; AGED; ANTIPSYCHOTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INJECTIONS, INTRAMUSCULAR; ISOXAZOLES; MALE; MIDDLE AGED; PALMITATES; PROSPECTIVE STUDIES; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TREATMENT FAILURE;

EID: 84858958502     PISSN: None     EISSN: 1471244X     Source Type: Journal    
DOI: 10.1186/1471-244X-12-26     Document Type: Article

References (35)

1. Keith SJ, Pani L, Nick B, Emsley R, San L, Turner M, Conley R, Scully P, Chue PS, Lachaux B. Practical application of pharmacotherapy with long-acting risperidone for patients with schizophrenia. Psychiatr Serv 2004, 55:997-1005. 10.1176/appi.ps.55.9.997, 15345759.
2. Kane JM, Aguglia E, Altamura AC. Guidelines for depot antipsychotic treatment in schizophrenia. Eur Neuropsychopharmacol 1998, 8:55-66. 10.1016/S0924-977X(97)00045-X, 9452941.
3. Nasrallah H. The case for long-acting antipsychotic agents in the post-CATIE era. Acta Psychiatr Scand 2007, 115:260-267. 10.1111/j.1600-0447.2006.00982.x, 17355516.
4. Rainer M. Risperidone long-acting injection: a review of its long term safety and efficacy. Neuropsych Dis Treat 2008, 4:919-927.
5. Samtani MN, Sliwa JK, Haskins JT, Alphs L, Stuyckens K, Herben V, Vermeulen A. Initiation dosing of deltoid intramuscular paliperidone palmitate in schizophrenia: pharmacokinetic rationale based on modeling and simulation. J Pharm Pract 2009, 22:216-217.
6. Nasrallah HA, Lasser R. Improving patient outcomes in schizophrenia: achieving remission. J Psychopharmacol 2006, 20(Suppl 6):57-61.
7. Kane JM. Treatment strategies to prevent relapse and encourage remission. J Clin Psychiatry 2007, 68(Suppl 14):27-30.
8. Olivares J, Rodriguez-Morales A, Diels J, Povey M, Jacobs A, Zhao Z, Lam A. Long-term outcomes in patients with schizophrenia treated with risperidone long-acting injection or oral antipsychotics in Spain: results from the electronic Schizophrenia Treatment Adherence Registry (e-STAR). Eur Psychiatry 2009, 24(5):287-296. 10.1016/j.eurpsy.2008.12.002, 19195847.
9. Invega® Sustenna™ Prescribing Information last update July 2009, accessed on 28 Dec, 2009.
10. Hough D, Lindenmayer JP, Gopal S, Melkote R, Lim P, Herben V, Yuen E, Eerdekens M. Safety and tolerability of deltoid and gluteal injections of paliperidone palmitate in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2009, 33(6):1022-1031. 10.1016/j.pnpbp.2009.05.014, 19481579.
11. Samtani MN, Vermeulen A, Stuyckens K. Population pharmacokinetics of intramuscular paliperidone palmitate in patients with schizophrenia. A novel once-monthly, long-acting formulation of an atypical antipsychotic. Clin Pharmacokinet 2009, 48:585-600. 10.2165/11316870-000000000-00000, 19725593.
12. Gopal S, Gassmann-Mayer C, Palumbo J, Samtani MN, Shiwach R, Alphs L. Practical guidance for dosing and switching paliperidone palmitate treatment in patients with schizophrenia. Curr Med Res Opin 2010, 26:377-387. 10.1185/03007990903482772, 20001492.
13. Sheiner LB, Beal SL. Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm 1981, 9:503-512. 10.1007/BF01060893, 7310648.
14. Bruno R, Vivier N, Vergniol JC, De Phillips SL, Montay G, Sheiner LB. A population pharmacokinetic model for docetaxel (Taxotere): model building and validation. J Pharmacokinet Biopharm 1996, 24:153-172. 10.1007/BF02353487, 8875345.
15. Preston SL, Drusano GL, Berman AL, Fowler CL, Chow AT, Dornseif B, Reichl V, Natarajan J, Wong FA, Corrado M. Levofloxacin population pharmacokinetics and creation of a demographic model for prediction of individual drug clearance in patients with serious community-acquired infection. Antimicrob Agents Chemother 1998, 42:1098-1104. 105752, 9593134.
16. Barnes TR. A rating scale for drug-induced akathisia. Br J Psychiatry 1989, 154:672-676. 10.1192/bjp.154.5.672, 2574607.
17. Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 1970, 212:11-19.
18. Guy W. ECDEU Assessment Manual for Psychopharmacology, revised, U.S. Department of Health, Education, and Welfare publication (ADM) 76-338 1976, Rockville, MD: National Institute of Mental Health.
19. Kay SR, FiszbeinL A, Opler L. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987, 13:261-276.
20. Morosini PL, Magliano L, Brambilla L, Ugolini S, Pioli R. Development, reliability and acceptability of a new version of the DSM-IV Social and Occupational Functioning Assessment Scale (SOFAS) to assess routine social functioning. Acta Psychiatr Scand 2000, 101:323-329.
21. Hough D, Gopal S, Vijapurkar U, Lim P, Morozova M, Eerdekens M. Paliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled study. Schizophr Res 2010, 116(2):107-117. 10.1016/j.schres.2009.10.026, 19959339.
22. Kramer M, Litman R, Hough D, Lane R, Lim P, Liu Y, Eerdekens M. Paliperidone palmitate, a potential long-acting treatment for patients with schizophrenia. Results of a randomized, double-blind, placebo-controlled efficacy and safety study. Int J Neuropsychopharmacol 2010, 13(5):635-647. 10.1017/S1461145709990988, 19941696.
23. Pandina GJ, Lindenmayer JP, Lull J, Lim P, Gopal S, Herben V, Kusumakar V, Yuen E, Palumbo J. Randomized, Placebo-Controlled Study to Assess the Efficacy and Safety of Three Doses of Paliperidone Palmitate in Adults with Acutely Exacerbated Schizophrenia. J Clin Psychopharmacol 2010, 30(3):235-244. 10.1097/JCP.0b013e3181dd3103, 20473057.
24. Nasrallah HA, Gopal S, Gassmann-Mayer C, Quiroz JA, Lim P, Eerdekens M, Yuen E, Hough D. A controlled, evidence-based trial of paliperidone palmitate, an investigational long-acting injectable antipsychotic, in schizophrenia. Neuropsychopharmacology 2010, 35(10):2072-2082. 10.1038/npp.2010.79, 3055301, 20555312.
25. Gopal S, Hough DW, Xu H, Lull JM, Gassmann-Mayer C, Remmerie BM, Eerdekens MH, Brown DW. Efficacy and safety of paliperidone palmitate in adult patients with acutely symptomatic schizophrenia: a randomized, double-blind, placebo-controlled, dose-response study. Int Clin Psychopharmacol 2010, 25(5):247-256. 10.1097/YIC.0b013e32833948fa, 20389255.
26. Kane JM. Strategies for improving compliance in treatment of schizophrenia by using a long-acting formulation of an antipsychotic: clinical studies. J Clin Psychiatry 2003, 64(Suppl 16):34-40.
27. Olfson M, Marcus SC, Ascher-Svanum H. Treatment of schizophrenia with longacting fluphenazine, haloperidol, or risperidone. Schizophr Bull 2007, 33:1379-1387. 2779880, 17470444.
28. Karlsson P, Dencker E, Nyberg S, Mannaert E, Boom S, Talluri K, Rossenu S, Eriksson B, Eerdekens M, Farde L. Pharmacokinetics and dopamine D2 and serotonin 5-HT2A receptor occupancy of paliperidone in healthy subjects: Two open-label single-dose studies. Clin Pharm Ther 2006, 79:74. Abstract PIII-57.
29. Nyberg S, Farde L, Halldin C, Dahl ML, Bertilsson L. D2 dopamine receptor occupancy during low-dose treatment with haloperidol decanoate. Am J Psychiatry 1995, 152:173-178.
30. Kapur S. 5-HT2 antagonism and EPS benefits: is there a causal connection?. Psychopharmcol 1996, 457:35-39.
31. Kapur S, Zipursky RB, Remington G, Jones C, DaSilva J, Wilson AA, Houle S. 5-HT2 and D2 receptor occupancy of olanzapine in schizophrenia: a PET investigation. Am J Psychiatry 1998, 155(7):921-928.
32. Kapur S, Zipursky R, Jones C, Remington G, Houle S. Relationship between dopamine D2 occupancy, clinical response, and side effects: A double-blind pet study of first-episode schizophrenia. Am J Psychiatry 2000, 157:514-520. 10.1176/appi.ajp.157.4.514, 10739409.
33. Remington G, Mamo D, Labelle A, Reiss J, Shammi C, Mannaert E, Mann S, Kapur S. A PET study evaluating dopamine D2 receptor occupancy for long-acting injectable risperidone. Am J Psychiatry 2006, 163:396-401. 10.1176/appi.ajp.163.3.396, 16513859.
34. Samtani MN, Gopal S, Mayer CG, Alphs L, Palumbo JM. Dosing and switching strategies for paliperidone palmitate: Based on population pharmacokinetic modelling and clinical trial data. CNS Drugs 2011, 25(10):829-845.
35. Allison DB, Mentore JL, Heo M, Chandler LP, Cappelleri JC, Infante MC, Weiden PJ. Antipsychotic-induced weight gain: A comprehensive research synthesis. Am J Psychiatry 1999, 156:1686-1696.